← All trials
NCT06816992
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2025
- Primary completion
- May 31, 2026
- Completion date
- May 31, 2027
- First posted
- Feb 10, 2025
- Last posted
- Mar 20, 2025
- Enrollment
- 76
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oric PharmaceuticalsLead sponsor
- Johnson and JohnsonCollaborator
- Oric PharmaceuticalsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.